Viewing Study NCT02280993

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:23 AM

Ignite Modification Date: 2026-04-19 @ 2:47 AM

Study NCT ID: NCT02280993

Status: UNKNOWN

Last Update Posted: 2018-03-13

First Post: 2014-08-19

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Sponsor: Marjolein Spiering

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module